Herbal medicines as adjuvants for cancer therapeutics - PubMed (original) (raw)
Herbal medicines as adjuvants for cancer therapeutics
Chong-Zhi Wang et al. Am J Chin Med. 2012.
Abstract
In the United States, many patients, including cancer patients, concurrently take prescription drugs and herbal supplements. Co-administration of prescription medicines and herbal supplements may have negative outcomes via pharmacodynamic and pharmacokinetic herb-drug interactions. However, multiple constituents in botanicals may also yield beneficial pharmacological activities. Botanicals could possess effective anticancer compounds that may be used as adjuvants to existing chemotherapy to improve efficacy and/or reduce drug-induced toxicity. Herbal medicines, such as ginseng, potentiated the effects of chemotherapeutic agents via synergistic activities, supported by cell cycle evaluations, apoptotic observations, and computer-based docking analysis. Since botanicals are nearly always administrated orally, the role of intestinal microbiota in metabolizing ginseng constituents is presented. Controlled clinical studies are warranted to verify the clinical utility of the botanicals in cancer chemoprevention.
Figures
Figure 1
Chemical structures of representative ginsenosides characterized from American ginseng. Two major groups of ginsenosides are listed. PPD: protopanaxadiol; PPT: protopanaxatriol; G: ginsenoside; Q: quinquenoside; F: floralquinquenoside. Adapted from (Qi et al., 2011a).
Figure 2
Synergistic antiproliferative effects of ginseng extract and 5-FU in human HCT-116 colorectal cancer cells. Cell growth decreased significantly with the combined treatment of ginseng extract (0.2 and 0.3 mg/mL) and 5-FU (10, 50 and 100 μM) than with 5-FU alone. Ctrl: control; GE: ginseng extract. *, P < 0.01 vs. corresponding groups of 5-FU only. Adapted from (Fishbein et al., 2009).
Figure 3
Panaxadiol enhances antiproliferative effects of irinotecan in HCT-116 cells. The combination of panaxadiol and irinotecan significantly enhanced antiproliferative effects in the cells. PD: panaxadiol; IRN: irinotecan. *, P < 0.05; **, P < 0.01, vs. corresponding groups of IRN only. Adapted from (Du et al., 2012).
Figure 4
Effects of irinotecan and panaxadiol on cell cycle in HCT-116 cells. (A) Representative histograms of cell cycle distribution. (B) Percentage of each cell cycle phase with various treatments or with control. PD: panaxadiol; IRN: irinotecan. Adapted from (Du et al., 2012).
Figure 5
Effects of irinotecan and panaxadiol on HCT-116 cell apoptosis and expression of caspases 3 and 9. (A) Representative scatter plots of PI (y-axis) vs. annexin V (x-axis). (B) Irinotecan and/or panaxadiol on expression of caspases 3 and 9. Cells were treated with irinotecan 10 μM and/or panaxadiol 10 μM. Ctrl: control; PD: panaxadiol; IRN: irinotecan. *P < 0.05 vs. corresponding control groups. Adapted from (Du et al., 2012).
Figure 6
Metabolic pathways of ginsenoside Rb1. “ → ” denotes major pathways; “ ” denotes additional pathways. [P]: metabolites detected in plasma; [U]: metabolites in urine; [F]: metabolites in feces; [B]: metabolites in bile. ig: metabolites after oral administration; iv: metabolites after intravenous injection. Compound K (C–K) is a pharmacologically active ginsenoside metabolite. Adapted from (Qi et al., 2011b).
Similar articles
- Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer.
Yap KY, See CS, Chan A. Yap KY, et al. Recent Pat Food Nutr Agric. 2010 Jan;2(1):12-55. doi: 10.2174/2212798411002010012. Recent Pat Food Nutr Agric. 2010. PMID: 20653549 - Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening.
Kumar NB, Allen K, Bell H. Kumar NB, et al. Cancer Control. 2005 Jul;12(3):149-57. doi: 10.1177/107327480501200302. Cancer Control. 2005. PMID: 16062162 Review. - Pharmacokinetic profiles of anticancer herbal medicines in humans and the clinical implications.
Chen XW, Sneed KB, Zhou SF. Chen XW, et al. Curr Med Chem. 2011;18(21):3190-210. doi: 10.2174/092986711796391624. Curr Med Chem. 2011. PMID: 21671861 Review. - An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics.
Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W, Cai P. Wang Z, et al. Biosci Trends. 2018;12(3):220-239. doi: 10.5582/bst.2018.01144. Biosci Trends. 2018. PMID: 30012913 Review. - Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides.
Wang HY, Qi LW, Wang CZ, Li P. Wang HY, et al. Am J Chin Med. 2011;39(6):1103-15. doi: 10.1142/S0192415X11009433. Am J Chin Med. 2011. PMID: 22083984 Free PMC article. Review.
Cited by
- Breast Cancer Chemoprevention from Nano Zingiber officinale Roscoe.
Wardana AP, Kristanti AN, Aminah NS, Fahmi MZ, Raoov M, Indriani. Wardana AP, et al. Int J Nanomedicine. 2024 Nov 1;19:11039-11053. doi: 10.2147/IJN.S474611. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39502639 Free PMC article. - Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.
Jenča A, Mills DK, Ghasemi H, Saberian E, Jenča A, Karimi Forood AM, Petrášová A, Jenčová J, Jabbari Velisdeh Z, Zare-Zardini H, Ebrahimifar M. Jenča A, et al. Biologics. 2024 Sep 10;18:229-255. doi: 10.2147/BTT.S484068. eCollection 2024. Biologics. 2024. PMID: 39281032 Free PMC article. Review. - Mechanistic insights into Retama raetam's anti-proliferative and pro-apoptotic effects in A549 lung cancer cells: targeting PI3K/Akt pathway and ROS production.
Alshehri MA, Seyed MA, Panneerselvam C, Sayed SM, Shukry M. Alshehri MA, et al. Toxicol Res (Camb). 2024 Sep 2;13(5):tfae137. doi: 10.1093/toxres/tfae137. eCollection 2024 Oct. Toxicol Res (Camb). 2024. PMID: 39233844 - Effect of Pistacia Terebinthus (terebinth) resin extract on aggressive breast cancer cells.
Fırat K, Nisari M, Metin İ, Fırat YY, Karatoprak GŞ, Hamurcu Z. Fırat K, et al. Toxicol Res (Camb). 2024 Mar 24;13(2):tfae046. doi: 10.1093/toxres/tfae046. eCollection 2024 Apr. Toxicol Res (Camb). 2024. PMID: 38533180 - Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of action of Wang Bu Liu Xing (Semen vaccariae) for colorectal cancer.
Shi Y, Zhang Y, Liu J, Zhao Y, Liu W. Shi Y, et al. J Gastrointest Oncol. 2023 Apr 29;14(2):504-515. doi: 10.21037/jgo-23-83. Epub 2023 Apr 24. J Gastrointest Oncol. 2023. PMID: 37201075 Free PMC article.
References
- Al-Suhaimi EA, Al-Riziza NA, Al-Essa RA. Physiological and therapeutical roles of ginger and turmeric on endocrine functions. Am J Chin Med. 2011;39:215–231. - PubMed
- Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125:940–941. - PubMed
- Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 1999;58:1685–1693. - PubMed
- Aung HH, Dey L, Mehendale S, Xie JT, Wu JA, Yuan CS. Scutellaria baicalensis extract decreases cisplatin-induced pica in rats. Cancer Chemother Pharmacol. 2003;52:453–458. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 DK042086/DK/NIDDK NIH HHS/United States
- K01 AT005362/AT/NCCIH NIH HHS/United States
- AT004418/AT/NCCIH NIH HHS/United States
- P01 AT004418/AT/NCCIH NIH HHS/United States
- 5P30DK042086/DK/NIDDK NIH HHS/United States
- AT005362/AT/NCCIH NIH HHS/United States
LinkOut - more resources
Full Text Sources